268 related articles for article (PubMed ID: 32457999)
1. Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?
Frigault MJ; Nikiforow S; Mansour MK; Hu ZH; Horowitz MM; Riches ML; Hematti P; Turtle CJ; Zhang MJ; Perales MA; Pasquini MC
Blood; 2020 Jul; 136(1):137-139. PubMed ID: 32457999
[No Abstract] [Full Text] [Related]
2. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors.
Bersanelli M
Immunotherapy; 2020 Apr; 12(5):269-273. PubMed ID: 32212881
[No Abstract] [Full Text] [Related]
3. Optimizing Administration of CAR T-Cell Therapy During the COVID-19 Pandemic.
Bishop MR
Clin Adv Hematol Oncol; 2020 Jul; 18(7):400-403. PubMed ID: 32903251
[No Abstract] [Full Text] [Related]
4. Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab.
Gautier-Vargas G; Baldacini C; Benotmane I; Keller N; Perrin P; Moulin B; Caillard S
Kidney Int; 2020 Aug; 98(2):508-509. PubMed ID: 32505467
[No Abstract] [Full Text] [Related]
5. Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.
Ranger A; Haji R; Kaczmarski R; Danga A
Br J Haematol; 2020 Aug; 190(3):e128-e130. PubMed ID: 32480422
[No Abstract] [Full Text] [Related]
6. Cytokine Storm Drugs Move from CAR T to COVID-19.
Cancer Discov; 2020 Jul; 10(7):OF8. PubMed ID: 32371479
[TBL] [Abstract][Full Text] [Related]
7. Cytokine release syndrome in severe COVID-19.
Moore JB; June CH
Science; 2020 May; 368(6490):473-474. PubMed ID: 32303591
[No Abstract] [Full Text] [Related]
8. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.
Price CC; Altice FL; Shyr Y; Koff A; Pischel L; Goshua G; Azar MM; Mcmanus D; Chen SC; Gleeson SE; Britto CJ; Azmy V; Kaman K; Gaston DC; Davis M; Burrello T; Harris Z; Villanueva MS; Aoun-Barakat L; Kang I; Seropian S; Chupp G; Bucala R; Kaminski N; Lee AI; LoRusso PM; Topal JE; Dela Cruz C; Malinis M
Chest; 2020 Oct; 158(4):1397-1408. PubMed ID: 32553536
[TBL] [Abstract][Full Text] [Related]
9. Applying (or Not?) CAR-T Neurotoxicity Experience to COVID-19 Delirium and Agitation.
Mack AH; Schofield HL
Psychosomatics; 2020; 61(6):859-860. PubMed ID: 32739050
[No Abstract] [Full Text] [Related]
10. Tocilizumab administration in a refractory case of COVID-19.
Dastan F; Nadji SA; Saffaei A; Tabarsi P
Int J Antimicrob Agents; 2020 Aug; 56(2):106043. PubMed ID: 32502524
[No Abstract] [Full Text] [Related]
11. Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.
Hoiland RL; Stukas S; Cooper J; Thiara S; Chen LYC; Biggs CM; Hay K; Lee AYY; Shojania K; Abdulla A; Wellington CL; Sekhon MS
Br J Haematol; 2020 Aug; 190(3):e150-e154. PubMed ID: 32584416
[No Abstract] [Full Text] [Related]
12. Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19.
Hassoun A; Thottacherry ED; Muklewicz J; Aziz QU; Edwards J
J Clin Virol; 2020 Jul; 128():104443. PubMed ID: 32425661
[No Abstract] [Full Text] [Related]
13. Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection.
Callejas Rubio JL; Luna Del Castillo JD; de la Hera Fernández J; Guirao Arrabal E; Colmenero Ruiz M; Ortego Centeno N
Med Clin (Barc); 2020 Aug; 155(4):159-161. PubMed ID: 32532461
[TBL] [Abstract][Full Text] [Related]
14. Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience.
Shah V; Ko Ko T; Zuckerman M; Vidler J; Sharif S; Mehra V; Gandhi S; Kuhnl A; Yallop D; Avenoso D; Rice C; Sanderson R; Sarma A; Marsh J; de Lavallade H; Krishnamurthy P; Patten P; Benjamin R; Potter V; Ceesay MM; Mufti GJ; Norton S; Pagliuca A; Galloway J; Kulasekararaj AG
Br J Haematol; 2020 Sep; 190(5):e279-e282. PubMed ID: 32526039
[No Abstract] [Full Text] [Related]
15. Clinical outcome of coronavirus disease 2019 in haemato-oncology patients.
Aries JA; Davies JK; Auer RL; Hallam SL; Montoto S; Smith M; Sevillano B; Foggo V; Wrench B; Zegocki K; Agrawal S; Le Dieu R; Truelove E; Erblich T; Araf S; Okosun J; Oakervee H; Cavenagh JD; Gribben JG; Riches JC
Br J Haematol; 2020 Jul; 190(2):e64-e67. PubMed ID: 32420609
[No Abstract] [Full Text] [Related]
16. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
Marzolini C; Stader F; Stoeckle M; Franzeck F; Egli A; Bassetti S; Hollinger A; Osthoff M; Weisser M; Gebhard CE; Baettig V; Geenen J; Khanna N; Tschudin-Sutter S; Mueller D; Hirsch HH; Battegay M; Sendi P
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32641296
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary Embolism and Increased Levels of d-Dimer in Patients with Coronavirus Disease.
Griffin DO; Jensen A; Khan M; Chin J; Chin K; Saad J; Parnell R; Awwad C; Patel D
Emerg Infect Dis; 2020 Aug; 26(8):1941-1943. PubMed ID: 32348233
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19.
Gade AR; Alavala H; Allam SR
Kidney Int; 2020 Oct; 98(4):1054. PubMed ID: 32650019
[No Abstract] [Full Text] [Related]
19. Cytokines and COVID-19: friends or foes?
Rokni M; Hamblin MR; Rezaei N
Hum Vaccin Immunother; 2020 Oct; 16(10):2363-2365. PubMed ID: 32841579
[TBL] [Abstract][Full Text] [Related]
20. Manufacturing and Management of CAR T-Cell Therapy in "COVID-19's Time": Central Versus Point of Care Proposals.
Ortiz de Landazuri I; Egri N; Muñoz-Sánchez G; Ortiz-Maldonado V; Bolaño V; Guijarro C; Pascal M; Juan M
Front Immunol; 2020; 11():573179. PubMed ID: 33178200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
